| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg/15px-SARS-CoV-2_(Wikimedia_colors).svg.png){kind=small} COVID-19 portal |
202-CoV is a COVID-19 vaccine candidate developed by Shanghai Zerun Biotechnology Co., Ltd., Walvax Biotech.[1][2][3] It is one of several candidates under development by Walvax.
YouTube Encyclopedic
-
1/2Views:16 8991 786 527
-
MT 103/202 COV, CASH, MANUAL DOWNLOAD, ATV , IP/IP ,SPECIAL TRANSFER, SEPA, SCT, - SWIFT FUNDING
-
What is a coronavirus? - Elizabeth Cox
Transcription
Development
In May 2020, the Bill & Melinda Gates Foundation awarded Shanghai Zerun Biotechnology a $1,000,000 USD vaccine development grant to "support research and development for COVID-19 response".[4]
In July 2021, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop COVID-19 vaccine candidates against both the original strain of SARS-CoV-2 and its newer variants.[3] As of October 2022, CEPI had provided up to $25.1 million USD towards 202-CoV, but had ceased further funding.[5] The chimeric protein candidate remains in Phase I clinical trials.
References
- ^ Clinical trial number NCT04982068 for "Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
- ^ Clinical trial number NCT04990544 for "Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
- ^ a b "CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine". Coalition for Epidemic Preparedness Innovations. 21 July 2021. Retrieved 30 August 2021.
- ^ "Shanghai Zerun Biotechnology Co., Ltd". Bill & Melinda Gates Foundation. May 2020. Archived from the original on 21 October 2022. Retrieved 21 October 2022.
- ^ "Our portfolio". Coalition for Epidemic Preparedness Innovations (CEPI). Archived from the original on 21 October 2022. Retrieved 21 October 2022.
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
.svg/18px-SARS-CoV-2_(Wikimedia_colors).svg.png){kind=small}
.png/32px-SARS-CoV-2_(CDC-23312).png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 19 February 2024, at 17:34